RVNC - These Analysts Lower Their Forecasts On Revance Therapeutics After Q1 Results | Benzinga
Revance Therapeutics, Inc. (NASDAQ:AKAM) posted a loss for its first quarter on Thursday.
Revance Therapeutics posted a GAAP loss of 54 cents per share, compared to market expectations for a loss of 63 cents per share. The company's quarterly sales came in at $51.936 million versus estimates of $56.634 million, according to data from Benzinga Pro.
“We are very pleased to see the DAXXIFY strategy change continue to drive the desired momentum and market share gains. Notably, we saw a healthy uptick in volume both on a year-on-year basis, where ...